Reactive oxygen species (ROS) are produced in phagocytic cells by NADPH oxidase, a complex that transports electrons across membranes and generates superoxide anion from molecular oxygen. This enzyme is assembled from a membranespanning flavocytochrome b 558 , composed of Nox2 (also called gp91 phox ) and p22 phox and four cytosolic factors (p47 phox , p67 phox , p40 phox , and Rac) that associate with the flavocytochrome to form an active enzyme (40) . Chronic granulomatous disease, characterized by defective microbial killing by phagocytic cells, is caused by defects or deficiencies in any one of four oxidase components: Nox2, p22 phox , p47 phox , or p67 phox (40) . An essential role for Rac1 or Rac2 in NADPH oxidase activation was also identified in cell-free reconstitution studies (1, 32) . This role was later confirmed in an oxidase-deficient patient who expressed mutant Rac2 (5) and in mice rendered genetically deficient in Rac2 (48) . Recently, several novel homologs of the catalytic, electron carrier component of NADPH oxidase (gp91 phox or Nox2) have been described in a variety of nonphagocytic cells (22, 36) . This new NADPH oxidase or Nox family encompasses seven enzymes identified in humans: Nox1, Nox2 (gp91 phox ), Nox3, Nox4, Nox5, Duox1, and Duox2. Nox1 and Nox3 are the closest homologs of Nox2 in terms of structure and function. Nox1 is detected in abundance in the colon and at lower levels in uterus, prostate, and vascular smooth muscle and endothelial cells (2, 50) . Although originally suggested to function as a promitogenic oxidase, Nox1 more likely functions as a host defense oxidase (19, 29) , like Nox2, and may have physiological and pathological roles in vascular tissue (2, 38) . Nox3 mRNA was detected in several fetal tissues by reverse transcription-PCR, including kidney, liver, lung, and spleen (12, 31) . Recently, a unique role for this oxidase was revealed within the inner ear (vestibular system) by positional cloning studies that mapped genetic lesions causing the head tilt (het) phenotype in mice (45) . Mice with Nox3 mutations exhibit impaired otoconial morphogenesis and defects in perception of gravity and balance. Subsequently, Nox3 expression was detected in the cochlear system, and it was suggested that Nox3-derived ROS could contribute to hearing loss and balance problems (8) .
Both the Nox1 and Nox3 oxidases appear to function as multicomponent enzymes similar to the phox (Nox2-based) system (7, 8, 14, 15, 21, 22, 29, 54, 55) . Nox1 expressed alone produces little superoxide, although its activity is dramatically enhanced in the presence of two cofactors (Noxo1 and Noxa1) that are detected in colon epithelium (7, 21, 54) . Noxo1 was proposed to act as a "Nox organizer" based on structural and functional similarities with p47 phox , which is a multimodular adaptor protein that bridges interactions between the flavocytochrome b 558 and p67
phox by binding to both p22 phox and p67
phox . Noxa1 was designated as a "Nox activator" based on its homology to p67 phox , which binds to Rac1 or Rac2 and promotes electron flow through the flavocytochrome in a GTPdependent manner (10) . The phagocytic oxidase can be reconstituted in vitro in the absence of p47 phox , when p67 phox and Rac1 are provided in excess (18, 34) or when p67 phox is adapted with the membrane-binding sequences of Rac1, although GTPbound Rac is still required for activation (3, 23, 24, 42) . Noxa1 was shown to bind Rac1 in a GTP-dependent manner (54) , although its role as a Nox1 regulator involving Rac1 has not been demonstrated directly. Both the human and murine Nox1 systems (comprising Nox1, Noxo1, and Noxa1) exhibit high constitutive activity, while activity of the human system is significantly enhanced by cellular activation in several cell types (7, 21, 28, 54) . Recently, several groups examined involvement of the Nox1 or Nox2 (phox) regulators in Nox3 activity and showed that this enzyme is less subject to the tight cofactordependent controlling mechanisms observed with Nox1 or Nox2 (8, 15, 55) . Furthermore, there has been no direct evidence for Rac-dependent regulation of Nox3 activity (55) .
In this study we examine the multicomponent nature (subcellular targeting, assembly, and activation) of Nox1-and Nox3-based oxidases in transfected cell models by systematically expressing wild-type and mutated forms of various oxidase components. We present evidence indicating that Nox1 and Nox3 are modulated by Rac1 and that this involves the Rac-binding Nox activators, Noxa1 and p67 phox . We also show that Noxo1 acts as an adaptor protein targeting Noxa1 to the plasma membrane and that p22 phox is targeted to the plasma membrane when either Nox1 or Nox3 is coexpressed. Finally, using a plasma membrane-targeted form of Noxa1, we reconstitute Noxo1-independent Nox1 activity, which is critically dependent on Rac1.
MATERIALS AND METHODS
Materials. Diphenyleneiodonium chloride (DPI) and superoxide dismutase (SOD) were purchased from Sigma-Aldrich and EMD Biosciences, respectively. Mouse monoclonal antibodies (Abs) against human Rac1 and ␤-tubulin were from Upstate Biosciences and Sigma-Aldrich, respectively. Rabbit polyclonal anti-V5 peptide horseradish peroxidase Ab and rabbit polyclonal anti-green fluorescent protein (anti-GFP) Ab were from Invitrogen and Clontech, respectively. Rabbit polyclonal Ab was raised against recombinant glutathione S-transferase (GST) fused to full-length mouse Noxa1, produced in Escherichia coli using pGEX-4T1 (Amersham Biosciences). Goat polyclonal Abs against human p47 phox and p67 phox were described previously (39) . Mouse monoclonal Ab against p22 phox (no. 449) was a kind gift from Dirk Roos (57). Rac1 Validated Stealth RNAi (RNA interference) DuoPak and Stealth RNAi Negative Control Medium GC Duplex were obtained from Invitrogen, and Rac1 Silencer Predesigned siRNA (short interfering RNA) and Silencer Negative Control no. 1 siRNA were from Ambion.
Cell culture. All cell culture reagents were obtained from Invitrogen, unless indicated otherwise. Human HEK293 cells (ATCC) were maintained in Eagle's minimal essential medium containing 10% heat-inactivated fetal bovine serum (FBS; HyClone Laboratories), 1 mM sodium pyruvate, 100 M nonessential amino acids, and antibiotics (100 units/ml penicillin and 100 g/ml streptomycin) at 37°C in 5% CO 2 . CHO-K1 cells (ATCC) were maintained in Ham's F-12 medium containing 10% heat-inactivated FBS and antibiotics at 37°C in 5% CO 2 . HT-29 cells (ATCC) were maintained in McCoy's 5A medium (modified) containing 10% heatinactivated FBS and antibiotics and grown in 5% CO 2 at 37°C.
Construction of plasmids. The pcDNA3.1 plasmids (Invitrogen) containing the complete coding sequence of human Nox1, Nox2, p51 nox (Noxa1), p47 phox , p67 phox , and p22 phox were described previously (20, 21) . The full coding sequence for human Nox3 was amplified by PCR using fetal kidney first-strand cDNA (Stratagene) using specific primers designed from previously reported sequence (GenBank accession number NM_015718) and cloned into pcDNA3.1. Human p41 nox (Noxo1␤) in pcDNA3.1 was made by adding codon Lys 50 to Noxo1␣ (21) using the QuikChange II XL site-directed mutagenesis kit (Stratagene). Fulllength Noxo1␤ and a C-terminally truncated mutant of Noxo1␤ (amino acids [aa] 1 to 319) lacking the proline-rich region (PRR; aa 320 to 329) that interacts with the C-terminal SH3 domain of Noxa1 were amplified by PCR, cloned into pcDNA3.1D/V5-His-TOPO (Invitrogen), and designated Noxo1-V5 and Noxo1 (⌬PRR)-V5, respectively. Full-length Noxo1␤ was amplified by PCR and cloned into the EcoRI and BamHI sites of pEGFP-N1 (Clontech) and designated Noxo1-GFP. We confirmed that Noxo1-GFP supports Nox1 activity in the presence of Noxa1 at levels comparable to those of unfused, native Noxo1 (data not shown) (14) . The cDNAs encoding human wild-type Rac1, Rac1(Q61L), Rac1(T17N), and Rac1(G30S) were described previously (35) ; these cDNAs were amplified by PCR and cloned into pCMV-Myc (Clontech) to express N-terminal, c-Myc epitope-tagged versions of these proteins. Mouse Rac1 in pEGFP-C1 (Clontech) was described previously (56) . Human Noxa1 and p67 phox coding sequences were adapted with the C-terminal, polybasic region of Rac1 (KKRKRK; aa 183 to 188) and isoprenylation "CAAX" motif of Rac1 (CLLL; aa 189 to 192) by PCR amplification (see Fig. 2B and Fig. 9D ), using specific reverse primers that provided these sequences, and then cloned into pcDNA3.1; the fused constructs were designated Noxa1(pp) and p67 phox (pp), respectively. All other indicated amino acid mutations, Noxa1(R103E), Noxa1(pp, R103E), Noxa1(W436R), Noxa1(R103E, W436R), Noxo1(W197R), p67 phox (R102E), p67 phox (pp, R102E), and p47 phox (W193R) in pcDNA3.1 and Noxo1(W197R) in pcDNA3.1D/V5-His-TOPO, were produced using the QuickChange II XL sitedirected mutagenesis kit. All modified expression vectors were sequenced to confirm their identities.
Cell fractionation and immunoblotting. Cells were sonicated in disruption buffer (44) in the present of protease inhibitor cocktail (Sigma-Aldrich), and the sonicate was centrifuged for 10 min at 10,000 ϫ g. The supernatant was further centrifuged for 1 h at 100,000 ϫ g. The pellet was defined as the membrane fraction, and the supernatant was defined as the cytosolic fraction. Western blotting was performed on proteins transferred to nitrocellulose membranes, preblocked in 5% nonfat dry milk in Tris-buffered saline (TBS) containing 0.03% Triton X-100 (TBST), and probed with primary antibody prepared in TBST at the dilutions indicated: Noxa1, 1:1,000; Rac1, 1:2,000; p47 phox , 1:2,000; p67 phox , 1:2,000; ␤-tubulin, 1:2,000; V5-horseradish peroxidase, 1:5,000; GFP, 1:2,000. Bound antibodies were detected with secondary antibody-peroxidase conjugates using the ECL detection system (Amersham Biosciences). In the case of fractionation studies using synthetic siRNA, suppressed levels of Rac1 protein were confirmed using aliquots of total lysates in each experiment.
Confocal fluorescence imaging studies. Cells (HEK293 or CHO-K1) were seeded on 35-mm glass-bottom dishes (MatTek Chambers) and transfected using FuGENE 6 (Roche Applied Science). At 40 to 48 h after the transfection, cells were fixed using 10% formalin in neutral buffered solution (Sigma-Aldrich). After permeabilization with TBS containing 0.3% Triton X-100 for 10 min, the fixed cells were stained for 2 h at room temperature (RT) using each primary antibody (Noxa1, p67 phox , p22 phox , or Rac1) at 1:200 dilutions (TBST with 5% bovine serum albumin). Secondary antibody-fluor conjugates (anti-rabbit antibody-Alexa 488 or anti-mouse or anti-goat antibody-Alexa 594; 1:2,000 dilutions) were applied for 0.5 h at RT. Confocal imaging was performed using a TCS-SP2 ABOS confocal laser scanning fluorescence microscope (63ϫ oil) (Leica Microsystems GmbH).
Rac1 activation assay. Rac1 activation assays were performed using the Rac1 activation assay kit (Upstate Biosciences) according to the manufacturer's suggested protocol. Briefly, cells (HEK293 or CHO-K1) grown in 10-cm dishes were harvested using 500 l of lysis/wash buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and 20 g/ml leupeptin). Cell lysates were centrifuged for 5 min at 3,000 ϫ g, and the resulting supernatants were mixed with 10 g of GST-PAK1-CRIB conjugated to glutathione-agarose beads and rocked at 4°C for 1 h. For positive and negative control experiments, 100 M GTP␥S or 1 mM GDP was added in 500 l of the resulting supernatant described above. After the mixture was rocked for 15 min at RT, the supernatant was mixed with GST-PAK1-CRIB-conjugated glutathione-agarose beads and rocked at 4°C for 30 min. After three washes, the beads were resuspended in Laemmli sample buffer, and the proteins bound to PAK1-CRIB were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed with Rac1 antibody (Upstate Biosciences).
Cell transfections and ROS production assays. Cells were seeded in six-well dishes at 250,000 cells/well (HEK293 cells), 75,000 cells/well (CHO-K1 cells), or 700,000 cells/well (HT-29 cells) for 48 h prior to transfection. Cell transfections were performed in serum-free medium using 6 l of FuGENE 6 prepared in complexes with plasmid DNAs (HEK293 and CHO-K1 cells, total, 2 g/well; 0.5 g of Nox1 or Nox3, plus 0.5 g each of other expression vectors or pcDNA3.1 [control] plasmid; HT-29 cells, 0.5 g each of expression vectors or pcDNA3. 1 [control] plasmid without Nox1), using the manufacturer's suggested protocol; in studies expressing mutant products, equal moles of plasmid were used in place of wild type. The cells were fed 5 h posttransfection with complete medium and were assayed 48 h after transfection. Trypsinized cells were assayed for ROS release (with or without activation with 2 g/ml phorbol myristate acetate VOL. 26, 2006 ASSEMBLY AND ACTIVATION OF Nox1 AND Nox3
[PMA]) by superoxide dismutase-sensitive chemiluminescence methods using the Diogenes reagent (National Diagnostics), as described previously (21) . The reagent has 10,000 times greater sensitivity for superoxide than does hydrogen peroxide (J. Kitzler [National Diagnostics], personal communication). RNAi-mediated silencing of Rac1. Rac1-specific short hairpin RNAs (shRNAs) were expressed in pSUPER-gfp, a Neo-resistant vector from Oligoengine (Seattle, WA). Four sequences of 19 or 21 nucleotides in length specific for human Rac1 cDNA (GenBank accession number NM_006908) were selected for synthesis of shRNA. Their sequences (5Ј-ACCGGTGAATCTGGGCTTA-3Ј, 5Ј-ACACTC CCATCATCCTAGT-3Ј, 5Ј-CCTTTGTACGCTTTGCTCA-3Ј, and 5Ј-GCTAAT AAGTGCTTTCCTTAG-3Ј), corresponding to nucleotides relative to the ATG translational initiation site (147 to 165, 320 to 338, 618 to 636, and 1664 to 1684, respectively) were cloned into BglII and HindIII sites of the vector; these vectors were named pSUPER-Rac1-147, pSUPER-Rac1-320, pSUPER-Rac1-618, and pSUPER-Rac1-1664, respectively. The constructs were sequenced to confirm their identities. In the case of RNAi studies using synthetic siRNAs, the following Rac1-specific or negative control RNAs were used: Rac1 Validated Stealth siRNA-2 (5Ј-AGGGUCUAGCCAUGGCUAAGGAGAU-3Ј), Stealth RNAi Negative Control Medium GC, Rac1 Silencer Pre-designed siRNA (siRNA identification: 214526, GCCACUACAACAGAAUUUU), and Silencer Negative Control no. 1 siRNA.
For ROS production assays, HEK293 cell transfections were performed as described above, using 0.1 g of Nox1 or Nox3, plus 50 ng each of other regulator plasmids, and 2.0 g of pSUPER-Rac1 or pSUPER-gfp (control) plasmid. In the case of Noxa1(pp), 0.2 g of Nox1 plus 0.1 g of Noxa1(pp) and 1.7 g of pSUPERRac1 or pSUPER-gfp (control) plasmid were used. For synthetic siRNA experiments, transfections of plasmid plus siRNAs were performed using 5 l of Lipofectamine 2000 and Opti-MEM I (Invitrogen), as described above. Suppressed Rac1 protein production was confirmed by immunoblotting, as described above.
Statistical analysis. Data are presented as the percentage of the maximally reconstituted oxidase activities observed in the absence of cell stimulation and were expressed as means Ϯ standard deviations (SD). For Nox1 experiments, full activity (100%) was defined with Nox1 plus Noxo1 plus Noxa1 coexpression; for Nox3, 100% was defined with Nox3 plus Noxo1; for Nox2, 100% was defined with Nox2 plus p47 phox plus p67 phox plus PMA. Mean activities were calculated from at least three independent transfection experiments, where each assay was performed in duplicate.
RESULTS

Subcellular localization of the Nox activator, Noxa1, is
Noxo1 dependent and Rac1 independent. Earlier studies have shown that Nox1 activity requires coexpression of two supportive cofactors, Noxo1 and Noxa1, which are homologous to p47 phox and p67 phox , respectively (7, 14, 21, 54) . The activity of the reconstituted human Nox1 system is significantly enhanced by cell stimulation in several transfected models, including NIH 3T3, HEK293, CHO-K1, Cos-7, and T84 cells (21, 29, 54) . Recently, Noxo1 was shown to accumulate on the plasma membrane through PX domain-lipid interactions, even without cell stimulation (14) . To explore assembly of the Nox1 system further, we examined the subcellular localization of Noxa1 in relation to Noxo1 in transfected HEK293 cells (Fig. 1A to D) . Noxa1 was detected with an antibody raised against recombinant murine Noxa1, which detects Noxa1 as a doublet band around 50 kDa by immunoblotting (Fig. 1E ), while Noxo1 subcellular localization was followed with a Noxo1-GFP fusion protein. Noxo1-GFP fluorescence occurs predominantly along the plasma membrane (Fig. 1A) , as described earlier (14) . The association of Noxa1 with the plasma membrane is dependent on Noxo1 (Fig. 1B) , since this localization pattern is disrupted by a Noxa1 SH3 domain mutation (W436R) previously shown to inhibit its interactions with the C-terminal PRR of Noxo1 (54) . Furthermore, Noxa1 accumulation along the plasma membrane is not observed in the absence of Noxo1 (Fig. 1C) . In this case, Noxa1 is found primarily in the cytosol, although a small portion of Noxa1 is also localized to ruffling membranes (Fig. 1C) , especially on the upper surfaces of cells (data not shown). The association of Noxa1 with ruffling membranes is not disrupted with mutant Noxa1(R103E) (Fig. 1D) , which no longer binds to Rac1 (54) . These results were confirmed in cell fractionation experiments, in which the Noxa1 plasma membrane-targeting protein, Noxo1-GFP, is detected entirely within the membrane (particulate) fraction, not in the cytosolic (soluble) fraction (Fig. 1E) . In contrast, the control unfused GFP protein is detected solely in the cytosolic fraction (Fig. 1F, right) . Although a portion of Noxa1 is detected in the membrane fraction, the amount in this fraction is increased significantly by cotransfection of Noxo1-GFP but not mutant Noxo1(W436R)-GFP (Fig. 1E, left) . The distribution of Noxa1 between membrane and cytosolic fractions is unaffected by the R103E mutation; by coexpression of the constitutively active form of Rac1, Rac1(Q61L); or by suppressing Rac1 production using two specific Rac1-targeted siRNAs ( Fig. 1F and G) . These observations demonstrate that Noxo1 can serve as an adaptor protein mediating interactions between Noxa1 and the plasma membrane, similar to the role of p47 phox in the Nox2 system. In addition, these experiments suggest that Rac1 does not affect the subcellular distribution of Noxa1.
Rac1 modulates Nox1 through its binding partner Noxa1. The importance of Noxo1 as a mediator of Noxa1-membrane interactions was then explored in Nox1-reconstituted cells. In the HEK293 cell model, the Diogenes-based luminescence assay of Nox1 activity supported by Noxo1 and Noxa1 coexpression is significantly stimulated by PMA, inhibited by DPI, and completely abolished by extracellular addition of SOD ( Fig. 2A) . However, Nox1 does not produce significant ROS when expressed alone or in pairwise combinations with Noxo1, Noxa1, or Rac1(Q61L), confirming the previously established model involving both Nox regulators ( Fig. 2A) . Based on several reports indicating that p47
phox is dispensable in cell-free reconstitution of the Nox2 system (18, 34) , particularly if p67 phox is adapted with membrane-binding sequences of Rac1 (3, 23, 24, 42) , we hypothesized that Noxa1 could support Nox1 activity in the absence of its membrane adaptor partner (Noxo1) if Noxa1 is directly targeted to the plasma membrane. Based on reports showing that the polybasic amino acids of Rac1 (KKRKRK; aa 183 to 188) together with the "CAAX" isoprenylation motif (CLLL; aa 189 to 192) can target proteins to the plasma membrane (16, 56), we constructed a plasma membrane-targeted form of Noxa1 involving a C-terminal fusion with these human Rac1 sequences (Fig. 2B ). As shown in Fig. 2C , both immunofluorescence and subcellular fractionation experiments confirmed that this modified form of Noxa1 [Noxa1(pp)] is efficiently targeted to the plasma membrane. Noxa1(pp) supports low but detectable levels of ROS release in Nox1-expressing cells in the absence of Noxo1, although cotransfection of Noxa1(pp) along with Rac1(Q61L) dramatically enhances ROS production by Nox1 (Fig. 2A) .
To characterize further the activation of Nox1 supported by Noxa1 in the absence of Noxo1, we examined the effects of Noxa1(R103E) and Rac1 mutants. As shown in Fig. 2A , Noxa1 alone does not support detectable Nox1 activity; however, cotransfection of Noxa1 and Rac1(Q61L) does (Fig. 2D ). This activity was completely abolished by the Noxa1(R103E) mutation that disrupts Rac1 binding. Noxo1 and Noxa1(pp) together support activity comparable to levels observed with the wild-type 2162 UEYAMA ET AL. MOL. CELL. BIOL.
proteins, although these proteins show a lower PMA-enhanced component (Fig. 2D) . Nox1 activity, supported by Noxa1(pp) alone, is also completely abolished with the Noxa1(pp, R103E) mutant. Nox1 activity reconstituted by Noxa1(pp) and Rac1 (Q61L) is significantly reduced with the Noxa1(pp, R103E) mutant. Finally, no activity is detected by substitution with Noxa1(pp, R103E) combined with Rac1(G30S) (Fig. 2D) . Thus, our observations demonstrate that Rac1 can modulate Nox1 through interactions with its binding partner, Noxa1. These experiments reveal close functional parallels in the assembly of Nox1-and Nox2-based oxidases, since Rac1 can modulate both systems through activator proteins (Noxa1 or p67 phox ), which in turn require critical adaptor or organizer proteins (Noxo1 or p47 phox ) to link them to the plasma membrane oxidase complex. Our findings on the contribution of Rac1 to Nox1 activation supported by the membrane-targeted form of Noxa1 [Noxa1(pp)] are analogous to observations on Nox2 reconstitution by similar, membrane-binding forms of p67 phox (3, 23) ; targeting of p67 phox fusion proteins containing the C-terminal, membrane-binding sequence of Rac1 was not sufficient to support Nox2 in vitro, and addition of the Rac1-GTP moiety is required for full activation.
Rac1 regulates the fully reconstituted Nox1 system. To explore further the involvement of Rac1 in the fully reconstituted system comprising Nox1, Noxo1, and Noxa1, we examined two transfected models, HEK293 and CHO-K1 cells. In the HEK293 cell model, neither the defective effector site mutant, Rac1(G30S), nor the constitutively active mutant, Rac1(Q61L), significantly affects Nox1 activity when reconstituted with both Noxo1 and Noxa1 (Fig. 3A) . However, in the reconstituted CHO-K1 cell model, Rac1(G30S) shows dominant-negative effects on both basal and PMA-stimulated Nox1 activities (Fig.  3B) . Furthermore, Rac1(Q61L) has an enhancing effect on FIG. 1. Noxo1-dependent and Rac1-independent subcellular localization of Noxa1 in HEK293 cells. A. Noxo1-GFP is detected predominantly along the plasma membrane. Coexpressed Noxa1 colocalizes with Noxo1 along the plasma membrane. B. The association of Noxa1 with the plasma membrane is disrupted by an SH3 domain mutation (W436R) that was shown to disrupt its interaction with the C-terminal, proline-rich region of Noxo1. C. Noxa1 expressed alone is localized primarily in the cytosol, although some Noxa1 accumulates at ruffling membranes (arrow). D. Localization of Noxa1 at ruffling membranes is not affected by a mutation [Noxa1(R103E)] that disrupts its interaction with Rac1. E. The Noxa1 antibody detects transfected Noxa1 as a doublet band around 50 kDa. Wild-type Noxa1 is detected in both cytosol and membrane fractions, consistent with fluorescence imaging. Membrane-associated Noxa1 increases by coexpression of Noxo1-GFP but not Noxo1(W436R)-GFP. Plasma membrane localizing protein, Noxo1-GFP, is detected predominantly in the membrane fraction. F. The fractionation of Noxa1 is not affected by a Noxa1 mutation at R103E or coexpression of Rac1(Q61L). Right, cytosolic (unfused) GFP is detected predominantly in the cytosol fraction. G. Fractionation of Noxa1 is not affected by two Rac1-suppressing siRNAs (Stealth and Silencer). Immunoblotting of total lysates confirms effective suppression of endogenous Rac1 by these siRNAs. no siRNA, transfection without siRNA. Bar, 10 m. Similar protein loading is confirmed by ␤-tubulin blotting. Similar results were obtained in four (A, B, C, D, and F) or three (E and G) independent experiments. VOL. 26, 2006 ASSEMBLY AND ACTIVATION OF Nox1 AND Nox3 2163 basal activity in the transfected cell model but little effect on PMA-stimulated activity. Wild-type Rac1 shows no statistically significant enhancing effect. Overexpression of a protein encoding the Cdc42/Rac-interactive binding (CRIB; aa 66 to 147) region of human p21-activated kinase 2 (hPAK2) shows a weaker inhibitory effect (10 to 15% inhibition) than that of Rac1(G30S) in CHO-K1 cells but not in HEK293 cells (data not shown). The absolute levels of Nox1 activity reconstituted by Noxo1 and Noxa1 in CHO-K1 cells are ϳ10% of that in HEK293 cells (data not shown). Interestingly, CHO-K1 cells show higher enhancing effects by PMA stimulation on oxidase activity than those observed in HEK293 cells (Fig. 3A and B) . To clarify the basis for the discrepancies in the effects of Rac1 mutants on Nox1 activity in the two reconstituted models, we examined the effects of Rac1 mutants on the reconstituted Nox2 system, which is known to involve Rac. Surprisingly, the Nox2 system transfected into HEK293 cells is not inhibited by the "dominant-negative" mutant Rac1(T17N), while this mutant does inhibit Nox2 activity when transfected into CHO-K1 cells (Fig. 3D) . The effector site mutant Rac1 (G30S) is an effective inhibitor of Nox2 in both cell models.
The greater effectiveness of the Rac mutants in CHO-K1 cells may, in part, relate to higher expression of the transfected Myc-tagged proteins relative to endogenous Rac1 levels (Fig.  3D) . Experiments examining the subcellular location of Rac1 in these cells, however, reveal other differences between the two models (Fig. 3E) . In HEK293 cells, a significant amount of endogenous Rac1 is concentrated along the plasma membrane within cortical regions of the cell, regardless of cellular stimulation. In contrast, endogenous Rac1 in CHO-K1 cells is detected primarily in a diffuse granular pattern throughout the cytoplasm (Fig. 3E) , with small amounts of Rac1 seen in ruffling membranes (data not shown). Finally, a Rac1 activation assay using the CRIB region of hPAK1 detected active Rac1 in unstimulated HEK293 cells but not in CHO-K1 cells (Fig. 3F) . Together, these observations could explain how overexpressed Rac1 mutants are less capable of perturbing endogenous Rac1 pools and altering oxidase activity (Nox1 or Nox2) in the HEK293 cell model.
To explore further the involvement of Rac1 in the complete Nox1 system, we used a vector-based method for expressing shRNA targeted to Rac1 in HEK293 cells. pSUPER-Rac1-147, pSUPER-Rac1-681, and pSUPER-Rac1-1664 significantly reduce detectable levels of endogenous Rac1 protein, while pSUPERRac1-320 has no apparent effect (Fig. 4A ). These observations correlate with significant inhibition of Nox1 activity by the effective Rac1-targeting vectors (Fig. 4B) . In particular, the most potent Rac1-suppressing vector, pSUPER-Rac1-681, strongly inhibits ROS production reconstituted by Nox1 and Noxa1(pp) (12.9% Ϯ 3.3% of control activity) (Fig. 4B) , a result consistent with data showing that Nox1 activity supported by Noxa1(pp) is completely abolished by Noxa1(pp, R103E) (Fig. 2C) . In addition, pSUPERRac1-681 significantly reduces the activity of Nox1 supported by Noxo1 and Noxa1 together (42.6% Ϯ 4.8% of control). These results suggest that Rac1 supports the fully reconstituted Nox1 system and indicate that, in the absence of Noxo1, the membranetargeted form of Noxa1 [Noxa1(pp)] is even more dependent on Rac1, since Noxa1(pp) does not support significant ROS production when endogenous Rac1 levels are suppressed. Thus, it appears that activation of both the Nox1 and Nox2 systems requires not only membrane targeting of the Nox activators (Noxa1 or p67 phox ) but also interaction with Rac. The inhibition of Nox1 activity by Rac1 silencing was also confirmed by the dose-dependent effects of synthetic siRNA (Fig. 4C) . The specificity of these Rac1 silencing effects was demonstrated by complete restoration of Nox1 activity inhibited by Rac1 Silencer siRNA (targeted to the 3Ј untranslated region of mRNA of human Rac1) following transfection of wild-type human Rac1 cDNA (Fig.  4C) . To demonstrate involvement of Rac1 in oxidase activity of colon epithelial cells, we examined the effects of mutant Rac1 and Rac1 siRNA in HT-29 cells, which express endogenous Nox1 (19, 20) . Cotransfection of these cells with Noxo1 and Noxa1 significantly enhances basal ROS production, which is inhibited by DPI (Fig. 4D ). This activity is enhanced further by Rac1(Q61L) (Fig. 4D) . Furthermore, ROS production enhanced by Noxo1 and Noxa1 is significantly inhibited by Rac1
Validated Stealth siRNA (targeted to the coding region of mRNA of human Rac1) and is restored by reintroduction of wild-type mouse Rac1, which differs within the targeted human sequence by 4 nucleotides (Fig. 4D) . Finally, we validated our Rac1 silencing approach used in these experiments by demonstrating that both the specific vector-based and synthetic siRNAs are also effective inhibitors of the Nox2 system reconstituted in the HEK293 cell model (Fig. 4F) . These observations on the involvement of Rac1 in Nox1 activity in the three transfected models confirm and extend the observations of Kawahara et al., who showed restoration of Ly294002-inhibited ROS production in guinea pig gastric pit cells by overexpressing an active mutant of Rac1 (28) . Nox1 is tightly controlled by multiple interactions involving Noxo1, Noxa1, Rac1, and p22 phox . We then studied the assembly and activation of the entire Nox1 system by examining the effects of disrupting various protein-protein interactions within this complex (Fig. 5A) . Basal Nox1 activity, reconstituted by Noxo1 and Noxa1, was reduced when the Rac1-binding mutant, Noxa1(R103E), was substituted for wild-type Noxa1, although the activity was still PMA stimulated. Also, the replacement of Noxa1 with the defective Noxo1-binding mutant, Noxa1(W436R), reduces the activity of Nox1, and the activity is still PMA stimulated. The effect of this mutant was confirmed further by expression of the complementary, C-terminal deletion mutant of Noxo1, Noxo1(⌬PRR). However, Nox1 activity supported by Noxo1 and Noxa1 was effectively abolished by the combined Noxa1 mutant Noxa1(R103E, W436R), by the complementary mutants Noxo1(⌬PRR) and Noxa1(R103E), or by the substitution of Noxo1(W197R) for Noxo1. Noxo1 (W197R) is the homologous point mutant of p47 phox (W193R) that disrupts the interaction between the SH3 domain of p47 phox and its PRR target site in p22 phox (17, 51) . Thus, the Nox1 system is effectively inhibited either (i) by disruption of the interactions of Noxa1 with both of its partners, Noxo1 and Rac1, thereby blocking access of Noxa1 to Nox1; or (ii) by disruption of the interaction between Noxo1 and p22 phox , thereby preventing the Noxo1-Noxa1 complex from interacting with the Nox1-p22 phox complex on the plasma membrane (Fig.  5B) . Together, these results demonstrate that full activation of the Nox1 system involves interactions between multiple components (Nox1, Noxo1, Noxa1, Rac1, and p22 phox ) that are functionally analogous to all of the critical components of the phagocytic (Nox2) system.
To demonstrate further p22 phox involvement in the assembly of the Nox1 system, we examined the subcellular localization of p22 phox in transfected cells. Endogenous p22 phox detected in HEK293 cells by confocal immunofluorescence microscopy has a reticular intracellular and perinuclear staining pattern (Fig. 6A) , and transfected p22 phox displays a staining pattern similar to that of endogenous p22 phox (Fig. 6B) cumulation of p22 phox on the plasma membrane (Fig. 6C ). These observations support the idea that Nox1 is stabilized through its association with p22 phox and that the two chains are transported together to the plasma membrane, where they provide a docking site for the Noxo1-Noxa1 complex. Thus, the activated enzyme would release ROS extracellularly, as is evident from the efficient scavenging effects of exogenously added SOD (Fig. 2A) .
Rac1 is involved in the Nox3 system. Nox3 also appears to function as a multicomponent system involving p22 phox and either the Nox or phox supportive cofactors (8, 15, 55) . We examined assembly and activation mechanisms of the Nox3 system with a focus on potential involvement of Rac1. As shown in Fig. 6D , transfection of Nox3 in HEK293 cells results in p22
phox transport to the plasma membrane, as observed with Nox1. Taken together with results showing that Nox3 activity is completely abolished by exogenous SOD (Fig. 7A and B) , the Nox3 system appears to release ROS into the extracellular medium, like the Nox1 system.
The physiologically relevant partners of Nox3 have not been clarified; therefore, we examined Nox3 activation using both Nox and phox supportive cofactors in both transfected cell models (Fig. 7) . Consistent with previous work (8, 15, 55) , transfected Nox3 exhibits detectable activity in the absence of any cotransfected organizer or activator protein. Interestingly, the activity of Nox3 alone was enhanced by Rac1(Q61L). Nox3 activity is maximally enhanced by cotransfection of Noxo1 alone and thus was used as a reference for comparing activities of all other Nox3 partners tested in the HEK293 and CHO-K1 cell models (Fig. 7A and B) . This activity is effectively abolished by substitution of Noxo1(W197R) for Noxo1, suggesting that the Noxo1-p22 phox interaction is critical for Nox3 activity supported by Noxo1. The combined expression of Noxa1 along with Noxo1 results in lower Nox3 activity than that supported by Noxo1 alone. This is consistent with recent findings by others (55) , suggesting that Noxo1 and Noxa1 together are not optimally suited as partners of Nox3 or act together to downregulate Nox3. Noxa1 alone supported low levels of Nox3 activity, but Rac1(Q61L) enhanced this activity. Nox3 activity supported by Noxa1(pp) was higher than that supported by Noxa1 or Noxa1 and Rac1(Q61L). The Nox3 activity supported by Noxa1 or Noxa1(pp) is dramatically decreased by the defective Rac-binding mutants (R103E) of these proteins. Thus, Nox3 activity appears to involve participation of both Rac1 and p22 phox interactions, although Nox3 is not subject to the same strict requirements for both Nox organizer and activator proteins that are observed with Nox1.
The Nox3 activity supported by phox regulators also appears to involve both p22 phox and Rac1 interactions. Surprisingly, the activities of Nox3 supported by p47 phox and p67 phox together are not significantly responsive to PMA, in both the transfected HEK293 and CHO-K1 cell models (Fig. 7C and D) . These are higher than those supported by Noxo1 alone. The activity of these systems is not dramatically inhibited by expression of the p47 phox (W193R) mutant, which disrupts the interaction between the SH3 domain of p47 phox and its PRR target site in p22 phox (17, 51 phox , or p67 phox and p47 phox , is significantly inhibited by pSUPER-Rac1-147, pSUPER-Rac1-681, or pSUPER-Rac1-1664 (vector-based RNAi). Data represent means Ϯ SD of at least three independent transfection experiments ‫,ء[‬ P Ͻ 0.05, compared with pSUPER (vector)]. B. Nox3 activity supported by p67 phox and p47 phox is significantly inhibited by Rac1 Stealth siRNA or Rac1 Silencer siRNA and restored by reintroduction of wild-type human Rac1 (0.5 g). Right panel, Western blotting confirms significant knockdown of endogenous Rac1 protein by Rac1 Silencer siRNA and production of Myc-tagged wild-type human Rac1 (lysates are from the same number of cells). Data represent means Ϯ SD of at least three independent transfection experiments ‫,ء(‬ P Ͻ 0.05, compared with no siRNA and negative-control siRNA).
VOL. 26, 2006 ASSEMBLY AND ACTIVATION OF Nox1 AND Nox3 2169 hancing effects on p67 phox or p67 phox (pp)-supported Nox3 activity (data not shown). Finally, the activity of Nox3 supported by p47 phox and p67 phox is partially inhibited by replacement with the p67 phox (R102E) mutant and almost completely abolished by coexpression of p47 phox (W193R) and p67 phox (R102E). Together, these results provide strong evidence for the involvement of Rac1 in the Nox3 system reconstituted with phox regulators in both transfected models.
To demonstrate further the involvement of Rac1 in the Nox3 system, we used the RNAi method to suppress Rac1 levels in the HEK293 cell model (Fig. 8) . Basal Nox3 activity is reduced to 60.2% Ϯ 9.2% of control levels with Rac1-specific siRNA (pSUPER-Rac1-681). Nox3 activity reconstituted by Noxa1 alone or by p67 phox alone is reduced to 48.2% Ϯ 8.0% or 48.6% Ϯ 3.8%, respectively, with pSUPER-Rac1-681. Finally, the full activity of Nox3 reconstituted by p47 phox and p67 phox together is also significantly reduced to 45.6% Ϯ 5.6% by pSUPER-Rac1-681 (Fig. 8A) . These results were confirmed by synthetic siRNA transfection experiments, in which Nox3 activity supported by p47 phox and p67 phox is inhibited more than 60% by two different reagents (39.9% Ϯ 8.2% or 37.8% Ϯ 5.0% by Rac1 Validated Stealth siRNA or Rac1 Pre-designed Silencer siRNA, respectively) (Fig. 8B) . Moreover, the activity inhibited by Silencer siRNA is completely restored by reintroduction of wild-type human Rac1 (Fig. 8B) .
To examine in more detail the basis of p67 phox -supported Nox3 activity, we explored the subcellular localization of p67 phox . As observed with Noxa1, p67 phox localizes to membrane ruffles (Fig. 9A) , with an appearance that closely resembles that of Rac1, consistent with recent observations in endothelial cells (11) ; however, this colocalization with Rac1 is not disrupted with Noxa1(R103E) (Fig. 9B ). These observations were confirmed in cellular fractionation experiments, which do not detect any changes in p67 phox distribution between membrane and cytosolic fractions in cells expressing the defective Rac-binding mutant form p67 phox (R102E) (Fig. 9C, left ) or in cells with suppressed Rac1 expression caused by siRNA (Fig. 9C, right) . In contrast, p67 phox (pp) is localized predominately on the plasma membrane (Fig. 9E) , consistent with its ability to support higher levels of Nox3 activity in comparison with wild-type p67 phox (Fig. 7C ). These observations suggest that Rac1 does not serve as a determinant in the subcellular localization of p67 phox .
DISCUSSION
In this study, we explored determinants of cellular targeting, assembly, and activation of the two closest homologs of the phagocytic (Nox2-based) NADPH oxidase, Nox1 and Nox3, and obtained evidence indicating that both of these multicomponent enzymes are regulated by the small GTPase Rac1. Both enzymes are supported by "activator" and "organizer" components, although their dependence on these regulators differs significantly (7, 8, 15, 21, 54, 55) . By systematically expressing wild-type and mutant forms of these components in transfected cell models, we assessed the relative contributions of these regulators and delineated a hierarchy of interactions governing assembly and activation of these novel oxidase complexes.
The molecular mechanisms controlling phagocytic oxidase activity have been studied extensively (6, 40, 43, 53) . The importance of multiple, specific protein-protein interactions in the assembly of this complex has been appreciated through analysis of a variety of molecular lesions observed in chronic granulomatous disease. For example, both flavocytochrome subunits are needed to stabilize this protein, enable complete posttranslational processing, and direct the mature protein to the plasma membrane (47, 58, 59 
